⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206905 | 0.74 | — | — | |
| SCHEMBL338079 | 0.72 | ALOX15 (0.52) | — | |
| SCHEMBL22469854 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL8848952 | 0.70 | ALOX15 (0.50) | — | |
| SCHEMBL196408 | 0.70 | — | — | |
| SCHEMBL27744756 | 0.70 | ALOX15 (0.50) | — | |
| SCHEMBL135308 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL275716 | 0.70 | ALOX15 (0.50) | — | |
| SCHEMBL372610 | 0.70 | — | — | |
| SCHEMBL1275886 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| US-9920040-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9908873-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-06 | — | — | US | disclosed |
| US-9856245-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-02 | — | — | US | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-08 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |